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ABSTRACT
Purpose To investigate the in vitro release of octreotide acetate, a
somatostatin agonist, from microspheres based on a hydrophilic
polyester, poly(D,L-lactide-co-hydroxymethyl glycolide)
(PLHMGA).
Methods Spherical and non-porous octreotide-loaded PLHMGA
microspheres (12 to 16 μm) and loading efficiency of 60–70%
were prepared by a solvent evaporation. Octreotide release
profiles were compared with commercial PLGA formulation
(Sandostatin LAR
®); possible peptide modification with lactic,
glycolic and hydroxymethyl glycolic acid units was monitored.
Results PLHMGA microspheres showed burst release
(~20%) followed by sustained release for 20–60 days,
depending on the hydrophilicity of the polymer. Percentage
of released loaded peptide was high (70–90%); >60% of
released peptide was native octreotide. PLGA microspheres
did not show peptide release for the first 10 days, after which it
was released in a sustained manner over the next 90 days;
>75% of released peptides were acylated adducts.
Conclusions PLHMGA microspheres are promising controlled
systems for peptides with excellent control over release kinetics.
Moreover, substantially less peptide modification occurred in
PLHMGA than in PLGA microspheres.
KEY WORDS acylation.aliphaticpolyester.controlled
release.microspheres.octreotide.PLGA.stability
INTRODUCTION
Microspheres of biodegradable polymers with poly
(D,L-lactide-co-glycolide) (PLGA) as main representative
have been widely studied for the prolonged release of
bioactive peptides (1–7). However, one of the issues in
peptide delivery using PLGA formulations is the formation
of peptide adducts as a result of acylation with lactic and
glycolic units (8,9). Acylation of, particularly, lysine residues
in peptides is catalyzed by the low pH that is generated
inside degrading PLGA microspheres due to the accumu-
lation of degradation products, i.e. lactic and glycolic acid
and their oligomers (10–14). The investigated options to
avoid chemical derivatization of peptides entrapped in
PLGA matrices, such as PEGylation and co-encapsulation
of water-soluble divalent cationic salts, resulted in less
acylation (15–17). However, it is obvious that these
approaches can not be generally applied, and consequently
other options need further exploration. Besides acylation,
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DOI 10.1007/s11095-011-0517-3incomplete and difficult-to-tailor release of peptides from
PLGA microparticles are other challenges hampering
widespread clinical application of these peptide formula-
tions (18,19). Within our department, a new hydrophilic
polyester, poly(lactide-co-hydroxymethyl glycolide)
(PLHMGA), has been developed (20,21). Protein-loaded
PLHMGA microspheres based on copolymers with differ-
ent ratios of D,L-lactide and hydroxymethyl glycolide
(HMG) (75/25, 65/35 and 50/50) were prepared using a
double-emulsion solvent evaporation method. Degradation
of the microspheres and release of model proteins (lysozyme
and BSA) were investigated. It was demonstrated that the
release of model proteins was governed by degradation of
the microspheres and that duration of the release could be
tailored from 2 weeks to 2 months (22,23). Spectroscopic
and chromatographic analysis as well as bioactivity meas-
urements (lysozyme) showed that the released proteins
retained their structural integrity.
In the present study we investigated the suitability of
PLHMGA microspheres for the release of a therapeutic
peptide, octreotide (structure shown in Fig. 1). This synthetic
peptide mimics the peptide hormone somatostatin and has
received FDA approval for the treatment of acromegaly (a
condition in which excess amount of growth hormone is
produced from the anterior pituitary) and gastroenteropancre-
atic neuroendocrine tumors (24,25). Because of its poor
pharmacokinetics (plasma half-life of about 100 min following
iv and sc injections (26,27)), sustained release octreotide
formulations based on PLGA microspheres have been
developed. One formulation named Sandostatin LAR
® made
with a PLGA-glucose star polymer is commercially available
a n du s e di nc l i n i c sf o rt h et r e a t m e n to fa c r o m e g a l ya n d
gastrointestinal tumors (28,29). However, previous studies with
octreotide-PLGA microspheres showed an incomplete and
difficult-to-tailor release (30). Importantly, HPLC and mass
spectrometric analysis demonstrated the presence of octreotide
d e r i v a t i v e s( l a c t o y la n dg l y c o y la d d u c t s )i nt h er e l e a s es a m p l e s
(17,30). It was hypothesized that a nucleophilic attack of the
primary amine groups present in the N-terminus and lysine
residue of the peptide on the electrophilic carbonyl ester
groups present in the PLGA backbone resulted in peptide
acylation (9,31).
Due to steric factors, the nucleophilic attack of octreotide
more readily occurred on glycolic acid rather than lactic
acid units (9). Because PLHMGA lacks glycolic acid units,
we hypothesized that octreotide encapsulated in PLHMGA
microspheres is less susceptible to acylation. Moreover, the
extra hydroxyl groups in PLHMGA increases the water-
absorbing capacity of the degrading polymer matrix and
facilitates the release of acid degradation products, thereby
preventing a pH drop (manuscript in preparation). It is
further anticipated that, as previously shown for BSA (23), the
release of the peptide can be tailored by the degradation
kinetics of the polymer, which in turn depends on the
copolymer composition. Therefore, the aim of this study was
to investigate PLHMGA microspheres of different composi-
tion for the controlled release of octreotide and compare the
release kinetics with octreotide release from Sandostatin
LAR
®. Possible modification of the released peptide was
investigated by HPLC and MALDI-TOF analysis.
MATERIALS AND METHODS
Materials
O-Benzyl-L-serine was purchased from Senn Chemicals AG
(Dielsdorf, Switzerland). D,L-lactide was obtained from
Purac, the Netherlands. N,N´-Dimethylformamide and
methyl-tert-butyl ether (MTBE), peptide grade dichloro-
methane (DCM), methanol, chloroform and tetrahydrofur-
ane (THF) were purchased from Biosolve (Valkenswaard,
the Netherlands). Benzyl alcohol was obtained from Merck
(Darmstadt, Germany). Toluene (Acros, Geel, Belgium) was
distilled from P2O5 and stored over 3Å molecular sieves
under argon. N,N´-Dimethylaminopyridine (DMAP) and
sodium azide (NaN3, 99%) were purchased from Fluka
(Zwijndrecht, the Netherlands). Disodium hydrogen phos-
phate dihydrate (Na2HPO4
.2H2O) and sodium dihydrogen
phosphate monohydrate (NaH2PO4
.H2O) were obtained
from Merck (Darmstadt, Germany). Polyvinyl alcohol
(PVA; Mw 30,000-70,000; 88% hydrolyzed) and tin (II)
2-ethylhexanoate (SnOct2) were from Sigma-Aldrich, Inc.,
USA. Pd/C (Palladium, 10 wt. % on activated carbon,
Degussa type E101 NE/W) was purchased from Aldrich,
Zwijndrecht, the Netherlands. Octreotide acetate (H2N-D-
Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol; MW=1,019 Da)
wasobtainedfromFeldan-bio(Quebec,Canada).Sandostatin
LAR
® (Batch No. S0090) was obtained from Novartis, Basel,
Switzerland.Accordingtothesupplier,theloadingcapacityof
Fig. 1 Structure of octreotide acetate; acylation most likely occurs at
positions 1 and 2 (http://www.chemblink.com/products/83150-76-9.htm).
Controlled Release of Octreotide from PLHMGA microspheres 111thisformulation was 20 mg peptide per 500 mg microspheres.
Unless otherwise stated, all chemicals were used as received.
Synthesis of Copolymers of 3S-(benzyloxymethyl)-6S-
methyl-1,4-dioxane-2,5-dione with D,L-lactide
3S-(benzyloxymethyl)-6S-methyl-1,4-dioxane-2,5-dione
(BMMG) was synthesized as described before by Leemhuis
et al.( 20). Copolymers of D,L-lactide and BMMG with
different monomer ratios (75/25, 65/35 and 50/50% D,
L-lactide/BMMG mol/mol) were synthesized by melt
copolymerization (Fig. 2)( 20).
As a representative example, for the 75/25 copolymer, D,L-
lactide (1,253 mg, 8.66 mmol) and BMMG (726 mg,
2.87 mmol) were transferred into a dried Schlenk tube under
adrynitrogenatmosphere.Benzylalcohol(12.54mg;37μlofa
352 mg/ml toluene stock solution) and SnOct2 (23.5 mg; 71 μl
of a 330 mg/ml toluene stock solution) were added as initiator
and catalyst, respectively. Toluene was removed under
vacuum, and the tube was sealed and immersed into a 130°
C oil bath for 16 h while stirring. After cooling to room
temperature, the obtained copolymer was dissolved in
c h l o r o f o r ma n ds u b s e q u e n t l yp r e c i p i t a t e di nc o l dm e t h a n o l .
The precipitate was collected by filtration and vacuum dried
to yield 1.86 g of poly(D,L-lactic acid-ran-benzyloxymethyl
glycolic acid) (PLBMGA) as a white solid. The copolymer was
dissolved in 300 ml distilled THF, and 10% w/w Pd/C was
added. The solution was stirred under a hydrogen atmosphere
for 16 h to remove the benzyl protecting group, and the
catalyst was subsequently removed by Hyflo filter. Evapora-
tion of THF yielded 1.5 g of poly(D,L-lactide-co-hydroxy-
methyl glycolide) (PLHMGA). Copolymers of 65/35 and 50/
50 (mol/mol D,L-lactide and BMMG) were synthesized using
the same method by adjusting the amount of BMMG and D,
L-lactide in the feed.
Polymer Characterization
1H NMR measurements of PLBMGA and PLHMGA
dissolved in CDCl3 were performed at 298 K on a Varian
Gemini-300 MHz spectrometer. Molecular weights of the
synthesized polymers were determined by GPC analysis
(Waters Alliance equipped with a Waters 2695 separating
module and a Waters 2414 refractive index detector). Two
PL-gel 5 μmM i x e d - Dc o l u m n sf i t t e dw i t hag u a r dc o l u m n
(Polymer Labs, Mw range 0.2-400 kDa) were used.
Calibration was performed with polystyrene standards
using THF as the mobile phase (1 ml/min). PLBMGA/
PLHMGA was dissolved in THF (5% w/v), and 50 μlw a s
injected into the column (22). The thermal properties of
the protected and deprotected copolymers were measured
using differential scanning calorimetry (TA instrument,
Q2000) as described before (23). The second cycle was
used to determine the glass transition temperature (Tg)o f
synthesized polymers.
Preparation of Octreotide Microspheres
Microspheres were prepared using a solvent evaporation
technique (22,32). In an optimized protocol, 50 μlo fa n
octreotide solution in reversed osmosis (RO) water
(200 mg/ml) was emulsified with 500 μl of dichloro-
methane solution of PLHMGA (220 mg, 25% w/w) by
using an IKA homogenizer (IKA Labortechnik Staufen,
Germany) for 30 s at the highest speed (30,000 rpm) to get
the primary emulsion. Next, 500 μl of a PVA solution
(1% w/w in 30 mM phosphate buffer, pH 7.4) was added
slowly, and the mixture was vortexed for 30 s at
30,000 rpm. The obtained w/o/w emulsion was then
transferred into a 5 ml PVA solution 0.5% (w/w) in 30 mM
phosphate buffer pH 7.4 while stirring. Continuous stirring
at room temperature for 2 h resulted in extraction/
evaporation of DCM. Finally, hardened microspheres were
collected by centrifugation (Laboratory centrifuge, 4 K 15
Germany) at 3,000 g for 3 min, subsequently washed 3
times with 100 ml RO water and freeze dried overnight. The
dried microspheres were stored at −25°C. Microspheres were
also prepared with other formulation and processing param-
eters (see Supplementary Material).
Microspheres Characterization
The microspheres’ size distribution was analyzed by an
Accusizer
th 780 (Optical particle sizer, Santa Barbara,
California, USA). Results are reported as volumetric mean
diameter.
The morphology of the microspheres after freeze-drying
was analyzed by scanning electron microscopy using a
Phenom
TM SEM (FEI Company, the Netherlands). The
samples were mounted onto a 12 mm diameter aluminum
Fig. 2 Synthesis of hydrophilic aliphatic polyesters based on lactic acid and glycolic acid with pendant hydroxyl groups, poly(lactic-co-hydroxymethyl
glycolic acid) (20).
112 Ghassemi et al.specimen stub (Agar Scientific Ltd., England) using double-
sided adhesive tape and were sputter-coated with platinum.
The octreotide loading of the microspheres (PLHMGA
as well as the PLGA/Sandostatin LAR
® formulation) was
determined using an HPLC method according to Wang
et al.( 33). In detail, about 10 mg of PLHMGA micro-
spheres were dissolved in 0.5 ml THF with gentle shaking.
Thereafter, 2 ml of diluent (0.2% w/v glacial acetic acid,
0.2% w/v sodium acetate and 0.7% w/v sodium chloride
in water) was added to precipitate the polymer. Next, the
mixture was incubated at room temperature for 20 min,
and the precipitated polymer was spun down by centrifu-
gation at 5,000 g for 1 min. The protein content in the
supernatant was measured by high performance liquid
chromatography (HPLC) using a Prosphere HP C4-300
column. A gradient elution method was used with a mobile
phase A (95% H2O, 5% ACN and 0.1% TFA) and a
mobile phase B (100% ACN and 0.1% TFA). The eluent
linearly changed from 100% to 40% A in 20 min with a
flow rate of 1 ml/min. Octreotide standards (5–200 μg/ml,
20 μl injection volume) were used for calibration, and
detection was done at 210 nm. Loading efficiency (LE) of
octreotide in microspheres is reported as the encapsulated
peptide divided by the total amount of peptide used for
encapsulation. Loading capacity (LC) is expressed as the
encapsulated amount of octreotide divided by the total dry
weight of the microspheres.
In Vitro Release Studies
The release of octreotide from PLHMGA and Sandostatin
LAR
® microspheres was studied in PBS (0.033 M
NaH2PO4, 0.066 M Na2HPO4, 0.056 M NaCl and
0.05% (w/w) NaN3, pH 7.4). About 30 mg of microspheres
was suspended into 1.5 ml of PBS buffer in eppendorf tubes
and incubated at 37°C under mild agitation using a circular
mixer (ASSISTANT RM 5). At the different time points,
the dispersion was centrifuged (3,000 g, 3 min), and 1 ml of
the supernatant was replaced with 1 ml of fresh buffer. The
microspheres were resuspended by gentle shaking, and the
dispersion was incubated at 37°C. The peptide concentra-
tion in the release samples was measured by HPLC as
described in section 2.5.3.
MALDI-TOF Analysis
Different release samples were analyzed using MALDI-
TOF (Applied Biosystems 4700, Foster City, CA, equipped
with a 200 Hz Nd:YAG laser operating at 355 nm).
Samples were diluted to 5 μg/ml in a solution of 3 mg/ml
Table II Characteristics of Octreotide-Loaded Microspheres (n=3) Prepared Using PLHMGAs of Different Composition and the Commercial PLGA
Formulation (Sandostatin LAR
®)
Polymer Copolymer composition Volume weight mean diameter (μm) LE
a (%) LC
b (%)
Poly(D,L-lactide-co-hydroxymethyl glycolide) 75/25 11.6±2.2 57.8±3.5 3.2±0.2
65/35 15.6±0.6 57.1±2.6 3.5±0.2
50/50 12.6±1.5 67.1±0.3 3.9±0.0
cPLGA (Sandostatin LAR
®) 50/50 65.0
dN.A. 4.1±0.1
aLE Loading efficiency
bLC Loading capacity
cThe results are from one single batch; LC was determined in triplicate
dNA data not available
Table I Characteristics of PLBMGA and PLHMGA Used in This Study
Polymer Feed ratio D,L
a/M
b Copolymer composition (NMR)
c Mn (kg/mol) Mw (kg/mol) Tg (°C)
PLBMGA 75/25 78/22 (11) 16 35 36
65/35 70/30 (15) 24 51 41
50/50 57/43 (21.5) 19 35 33
PLHMGA 75/25 80/20 (10) 13 30 49
65/35 69/31 (15.5) 22 45 47
50/50 51/49 (24.5) 17 31 48
aD,L D,L-lactide
bM Monomer BMMG (benzyloxymethyl methyl glycolide)
cThe numbers in brackets are correspondent to either BMGA or HMGA
Controlled Release of Octreotide from PLHMGA microspheres 113α-cyano-4-hydroxycinnamic acid dissolved in 1:1 acetoni-
trile/MilliQ (v/v) containing 0.1% (v/v) trifluoro acetic
acid. The sample (about 1 μl) was spotted onto a stainless
steel matrix-assisted laser desorption/ionization (MALDI)
plate. Analysis was performed in a reflectron positive ion
mode, and, typically, 3,000 shots/spectrum were acquired
in the MS mode.
RESULTS AND DISCUSSION
Synthesis and Characterization of PLHMGA
with Different Copolymer Composition
Benzyl protected hydroxymethyl glycolide (BMMG) and D,
L-lactide were copolymerized by ring opening polymeriza-
tion at different feed ratios (75/25, 65/35 and 50/50 mol
D,L-lactide/mol BMMG) in the melt at 130°C using
BnOH and SnOct2 as initiator and catalyst, respectively.
The protected copolymers (PLBMGA) were obtained in
high yields (>90%), and NMR analysis showed that the
copolymer composition closely matched that of the feed
(Table I). DSC analysis showed that the copolymers were
fully amorphous with a Tg ranging from 33 to 41°C
(Table I), which is in agreement with previous findings
(20,22,23). NMR analysis showed that catalytic hydrogena-
tion of PLBMGA resulted in quantitative removal of the
protecting benzyl groups to obtain PLHMGAs in a high
yield. As for the protected polymers, PLHMGA of different
composition were fully amorphous with a Tg of 47–49°C
(Table I). GPC analysis showed that the number average
molecular weights of synthesized polymers before and after
deprotection ranged from 13–24 kg/mol. The molecular
weight distributions were similar (Mw/Mn ~2) to those of
polyesters synthesized by ring opening polymerization of
lactide/glycolide in the melt (34).
Preparation and Characterization
of Octreotide-Loaded Microspheres
Octreotide-loaded microspheres were prepared using a
double emulsion/solvent evaporation technique as described
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Fig. 4 HPLC chromatograms of octreotide after 21 days incubation in
PBS pH 7.4 at 37°C (a) and after release from microspheres of PLHMGA
(65/35, b) and PLGA (c) after 21 days.
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Fig. 3 SEM analysis of microspheres: (a) PLHMGA 75/25, (b) PLHMGA
65/35, (c) PLHMGA 50/50 and (d) Sandostatin LAR
® (note the difference
in scale bar between (d) and (a–c).
114 Ghassemi et al.in section 2.4. The characteristics of the microspheres are
summarized in Table II.
Table II shows that the PLHMGA microspheres had
about the same size that ranged from 12–16 μm. The effect
of several formulation parameters, which are known to
have a possible influence on the loading efficiency, was
investigated (polymer concentration (35), volume of the
protein solution (36), addition of salt to the continuous
phase (37), volume of continuous phase (38), use of
methanol as solvent for octreotide (o/w method) (8) and
buffering the pH of the PVA phase at pH 7.4). The results
presented in the Supplementary Material show that the LE
was low (<30%) except for the formulation that was
prepared with a neutralized external phase (LE was
50–60%, Table II). Likely, the driving force for extraction
of octreotide from the internal to the external aqueous
phase during formation of the particles is low at pH 7.4
(which is close to the pI of octreotide (8.5)) because the
aqueous solubility of the peptide is low, resulting in an
enhanced loading efficiency and capacity. The LE was
independent of copolymer composition and is in agreement
with previous findings showing around the same LE of
octreotide in PLGA microspheres (33). The LC of the
Sandostatin LAR
® was 4.1±0.1, which is within the
experimental error equal to the load as specified by the
supplier (20 mg peptide per 500 mg formulation). SEM
analysis of the different microspheres of Table II showed
that the particles are spherical and essentially non-porous
(Fig. 3) and the average size by SEM corresponded well
with that of accusizer measurements (Table II). SEM
analysis of Sandostatin LAR
® shows particles with a bigger
size than the PLHMGA microspheres, in agreement with
accusizer measurements (average size around 65 μm,
Table II). Besides, SEM analysis also showed the presence
of some smaller irregularly shaped particles in Sandostatin
LAR
® (Fig. 3d).
In Vitro Release of Octreotide-Loaded PLGA/
PLHMGA Microspheres
The HPLC chromatogram of octreotide in PBS (pH 7.4)
incubated at 37°C for 21 days showed a sharp peak with a
retention time around 10 min (Fig. 4a). No other peaks
were detected, demonstrating that octreotide has a good
stability under the conditions applied for evaluation of the
release of the different octreotide formulations. However,
octreotide released from PLHMGA and PLGA micro-
spheres showed extra peaks with longer retention times
(11–12 min) originating from acylated octreotide adducts
(see MALDI-TOF Analysis section) as also observed by
Murty et al.( 30). It is remarked that the extent of peptide
modification is more pronounced after being released from
PLGA than from PLHMGA microspheres (compare
Fig. 4b, c). At the end of release study when the
microspheres were fully degraded (day 95 for PLGA
microspheres and day 60 for PLHMGA 65/35 micro-
spheres, respectively), mainly acylated peptide was released
from PLGA microspheres, whereas mainly native octreotide
was released from PLHMGA microspheres (Supplementary
Material 2 and 3,r e s p e c t i v e l y ) .I ts h o u l db es t r e s s e dt h a t
acylated octreotide adducts are formed during degradation
of the microspheres and not during their preparation, since
only native peptide was detected with HPLC when the
Table III Summary of In Vitro Release of Octreotide-Loaded PLHMGA Microspheres of Different Composition (n=3) and PLGA Microspheres in
PBS (pH 7.4) at 37°C
Batch % of the loaded
amount released
% burst release
a % native octreotide
c Microspheres
degradation (days)
Duration of release
PLHMGA 75/25 69.6±7.0 18.5±0.5 74.5±0.3 55 75
PLHMGA 65/35 82.1±5.0 21.1±0.2 65.6±1.5 35 60
PLHMGA 50/50 84.5±4.0 23.7±0.3 68.3±3.2 20 20
bPLGA 85 no 25 90 95
aDefined as the amount released after 24 h
bResults are from a single batch
cDefined with respect to the total octreotide that was released
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Fig. 5 In vitro release of octreotide from PLGA (the results are from one
study); (Δ) native octreotide, (▲) acylated octreotide and (○) total octreotide
(native and acylated octreotide adducts). The percentage of release is based
on the LC of PLGA microspheres detected by HPLC (Table II).
Controlled Release of Octreotide from PLHMGA microspheres 115loading capacity of the different microspheres was deter-
mined (data not shown).
Figure 5 shows the in vitro release of octreotide from
PLGA microspheres in PBS pH 7.4 during 95 days. After
95 days the PLGA microspheres were fully degraded, in
accordance to what has been reported by Spenlehauer et al.
(39). The formulation showed no burst release, and after
10–15 days peptide release started, which continued for the
next 80 days until a plateau value was reached at 85% of
the octreotide loading. The incomplete release can be due
to the formation of insoluble peptide residues (not visible
with naked eye) or to adsorption of the peptide to surfaces
with which it has been brought into contact. HPLC analysis
(see Fig. 4) makes it possible to differentiate between
octreotide that is released in its native form and in acylated
forms. Of the released peptide, 25% was unmodified
octreotide, whereas the remaining 75% was acylated
products (Fig. 5, Table III).
The release of octreotide from microspheres based on
PLHMGA of different hydrophilicity (different copolymer
composition (75/25, 65/35 and 50/50 mol/mol D,
L-lactide and BMMG (after deprotection: HMG)) was
studied. The results are shown in Fig. 6 and in the
Supplementary Material 4; the data are summarized in
Table III. Figure 6 shows the release of octreotide from
microspheres of PLHMGA 65/35. It appears that after a
burst (around 20% of the loading), which is probably
caused by nanopores present in the microspheres that are
not detected with SEM, octreotide was released in a
sustained manner for 60 days, and almost quantitative
release (80–90%) was obtained. Although also acylated
forms of the peptide were released, more than 65% of the
released amount was native octreotide, while PLGA micro-
spheres mainly released acylated octreotide, (Table III).
Fig. 7 Proposed mechanism of
reaction between peptide and
PLGA (18,40); the same mecha-
nism is also valid for the reaction of
a peptide with PLHMGA.
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Complete degradation of microspheres 
Fig. 6 In vitro release of octreotide fromPLHMGAmicrospheres(65/35) in
PBS pH 7.4 at 37°C: (▲) acylated octreotide, (Δ) native octreotide and (○)
total octreotide release (native and acylated octreotide adducts) (n=3).
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were fully degraded after 35 days, in line with our previous
study (23). The explanation for the continuation of the
release after visible microsphere degradation will be given
below (vide infra).
Microspheres of copolymer 50/50 showed, after a burst
(around 20% of the loaded amount), an almost zero order
release of the peptide for 20 days until 85% of the loaded
amount was released (of which 70% is native octreotide and
the remaining 30% is in the form of acylated peptide;
Supplementary Material 4 and Table III). Complete
degradation of the microspheres, occurred in 20 days.
Octreotide release from microspheres of the more slowly
degrading copolymer 75/25 (Supplementary Material 5)
was characterized by a burst (around 20% of the loaded
amount) followed by a sustained release for more than
60 days. In line with the results of PLHMGA 65/35 and
50/50 microspheres, around 70% of the released peptide
was native octreotide, whereas 30% was acylated adducts.
PLHMGA 75/25 microspheres degraded completely in
55 days. There is a tendency that the total released amount
of peptide decreases with increasing degradation time of the
particles. This might be due to the presence of polymer-
peptide conjugates in the release medium that are not
detected with the HPLC method (see Fig. 7 caption). Also,
adsorption of the peptide to surfaces to which it has been
exposed for longer times with increasing degradation time
might be responsible for this observation.
In our previous studies, the release of model proteins
lysozyme and BSA from microspheres of copolymer 50/
50, 65/35 and 75/25 was reported. It was concluded
that the release of these proteins was essentially governed
by degradation of the polymer matrices (22,23). The
present results show that degradation governs to some
extent the release of the peptide as well (the faster the
degradation of the particles, the faster its release).
Probably also diffusion plays a role, given the observation
that, after the burst, the PLHMGA microspheres released
the peptide without delay (as opposed to the protein
delivery studies). Obviously, the hydroxyl groups of the
polymer give sufficient water absorption to release the
peptide by diffusion.
In the present study, we observed that after complete
degradation of the microspheres (at day 35 for the
PLHMGA 65/35 microspheres, Fig. 6) the release of
octreotide still continued (from 62% of the loading at day
35 to 80% at day 60). This can be explained as follows. The
reaction of the copolymer and a nucleophile (e.g. lysine
residue) of the peptide results in the formation of a peptide-
polymer conjugate (step 1, Fig. 7). Likely, these polymer-
peptide conjugates have either limited solubility or are not
detected by the used HPLC method (30) due to their
heterogeneous character. The peptide-polymer conjugates
may still be present at the time the microspheres are fully
degraded and are slowly converted by hydrolysis during the
next days into peptide-LA/HMGA adducts (Fig. 7, step 2),
which are detected with HPLC, explaining the apparent
increase in release after degradation of the microspheres
(the apparent increase in total percentage of release is thus
due to acylated peptide adducts). The observation that after
full microspheres’ degradation the amount of released
native peptide indeed hardly increased supports the
above-mentioned explanation.
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Fig. 8 Mass spectrum of octreotide acetate after incubation of 21 days in
PBS at 37°C (a), after 21 days of release from Sandostatin LAR
® (b) and
PLHMGA microspheres of copolymer 65/35 (c).
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The structure of the released octreotide adducts was
investigated by MALDI-TOF analysis. Figure 8a shows
the mass spectrum of the native octreotide with only peaks
corresponding with octreotide H+(1,019 m/z) and that of
the Na-adduct (1,041 m/z). Figure 8b and c show the mass
spectra of octreotide released after 21 days from PLGA and
PLHMGA microspheres, respectively. Clearly, besides
native octreotide, also peaks with higher masses were
detected. In agreement with HPLC analysis (vide supra),
more extensive peptide derivatization is seen in octreotide
released from PLGA than from PLHMGA microspheres.
MALDI-TOF spectra of the octreotide released from
microspheres based on PLHMGA of different copolymer
composition were similar.
The attribution of the MALDI-TOF MS peaks to
different octreotide derivatives is summarized in Table IV.
The masses of the observed peaks of octreotide released
from PLGA microspheres can be fully ascribed to peptide
modified with lactic (octreotide-LA) and glycolic acid
(octreotide-GA) units. These products are formed as
suggested by Na et al.( 15) and Zhang et al.( 41). The
relative amounts of octreotide-GA (peak numbers 3 and 4,
Fig. 8b) was substantially greater (height ratio about 7/1)
than octreotide-LA (peak numbers 5 and 6, Fig. 8b). This
can be explained because the nucleophilic attack is more
hindered with lactic acid monomers as compared with
glycolic acid monomers (Fig. 9)( 8).
No octreotide-GA was detected in octreotide released
from PLHMGA microspheres due to the lack of glycolic
acid units in PLHMGA, while minor amounts of
octreotide-HMGA were observed instead. The ratio of
octreotide-LA to octreotide-HMGA was 1.6, 1.2 and 1.3
for copolymer 75/25, 65/35 and 50/50, respectively. The
50/50 copolymer contains 75% lactic acid units and 25%
HMGA units (Fig. 2). This means that if both units are
equally reactive with the peptide, a 3/1 ratio octreotide-LA
to octreotide-HMGA can be expected (for the peptide
released from the other PLHMGA microspheres, this ratio
would be even higher). Further, it should be mentioned that
in time the degrading polymers become richer in lactate
content (21,22), which would point to an even higher
expected ratio of octreotide-LA to octreotide-HMGA. It is
therefore concluded that acylation of octreotide preferen-
tially occurs by reaction with the HMGA esters. Likely, this
monomer unit due to its hydroxyl group is more hydrated
than the lactic acid units in the polymer chain, favoring
reaction with the peptide.
Based on the results (Fig. 5, peptide release from PLGA,
Fig. 6 peptide release from PLHMGA, Fig. 8 and
Table IV), it can be concluded that less peptide acylation
occurs during release from PLHMGA microspheres com-
pared to that of PLGA microspheres. Three factors might
contribute to the lower extent of peptide acylation in
degrading PLHMGA microspheres. First, as mentioned
above, the absence of the more reactive glycolic acid units
in PLHMGA slows down the acylation reaction (9). Second,
the increased degradation rate promotes the removal of the
HMGA units and thus reduces the adduct formation.
Third, it has been shown that the low pH generated inside
degrading PLGA matrices catalyzes the formation of
acylated peptide adducts (40). However, less acidification
of PLHMGA matrices occurs during degradation com-
Table IV Acylated Octreotide Adducts Detected by MALDI-TOF MS in Release Samples of PLHMGA and PLGA Microspheres (15,41)
Peak number Observed m/z Assigned structure (octreotide released from PLGA) Assigned structure (octreotide released from PLHMGA)
1,2 1019, 1041 Octreotide, Octreotide-Na Octreotide, Octreotide-Na
3,4 1077, 1099
aOctreotide-GA, Octreotide-GA-Na N.D.
5,6 1091, 1113
bOctreotide-LA, Octreotide-Na-LA Octreotide-LA, Octerotide-Na-LA
7,8 1107, 1129 N.D.
cOctreotide-HMGA, Octreotide-HMGA-Na
9,11 1135, 1157 Octreotide-GA-GA, Octreotide-Na-GA-GA N.D.
10,12 1149, 1171 Octreotide-LA-GA, Octreotide-Na-LA-GA N.D.
aOctreotide-GA octreotide-glycoyl adduct
bOctreotide-LA octreotide-lactoyl adduct
cOctreotide-HMGA octreotide-hydroxymethyl glycoyl adduct
ND not detected
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Fig. 9 Proposed explanation of reduced reactivity of nucleophilic species
with lactic acid monomers (8).
118 Ghassemi et al.pared to that of PLGA matrices (manuscript in prepara-
tion), likely due to the more hydrophilic character of
degrading PLHMGA matrices which favors the extraction
of formed water-soluble acidic degradation products.
CONCLUSIONS
Our data demonstrate that the release of octreotide from
PLHMGA microspheres can be tailored by the copolymer
composition and outperformed that of the commercial
octreotide formulation Sandostatin LAR
®. Importantly,
substantially less acylated octreotide adducts were formed
in degrading PLHMGA microspheres than in Sandostatin
LAR
® due to the lack of glycolic acid and less acidification.
To further decrease the acylation, PEGylation of octreotide
or co-encapsulation of excipients which can prevent the
nucleophilic attack of a peptide to the polymer backbone
(17,41) are logical options that warrant further investigation.
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